Targeted Therapy in Systemic Sclerosis.

Rambam Maimonides Med J · 2016 · PMC5101004 · PMID 27824545

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not quite reach statistical significanceno p-value reported

53 The primary end-point showed a treatment difference of −2.70 MRSS units in favor of tocilizumab at week 24 but did not quite reach statistical significance.

also in 679 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.